About Foundation Medicine
Foundation Medicine news and updates
Texas Oncology partnered with Foundation Medicine, Inc. on Apr 13th 22'.
Texas Oncology announced today that it has entered into an agreement with Foundation Medicine, a pioneer in molecular profiling for cancer, to provide Texas Oncology care teams with access to its Food and Drug Administration (FDA)-approved blood-based comprehensive genomic profiling (CGP) test, FoundationOne®Liquid CDx.
Jan 1, 2022 | businesswire.comClovis partners with Foundation Medicine, Inc.
Clovis collaborated with Foundation Medicine to use a next-generation sequencing panel to identify patients in this study with alterations in BRCA1/2, ATM, and in 13 other genes indicating homologous recombination deficiency.
Jan 1, 2020 | precisiononcologynews.comFoundation Medicine, Inc. partnered with Pfizer, Inc. on Jan 16th 18'.
Foundation Medicine said today it will partner with Pfizer to develop and commercialize companion diagnostics (CDx) for the pharma giant’s oncology portfolio, through a collaboration whose value was not disclosed.
Jan 1, 2018 | genengnews.comFoundation Medicine, Inc. is developing novel companion diagnostic assay for Lynparza
AstraZeneca has entered into a definitive agreement with Foundation Medicine, Inc. (Foundation Medicine) to develop a novel companion diagnostic assay for Lynparza (olaparib) to support its global development programme.
Sep 12, 2022 | nordiclifescience.orgFoundation Medicine, Inc. is developing FoundationOne CDx on Sep 21st 22'.
Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, and Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced a collaboration to develop FoundationOne ® CDx as a companion diagnostic for Day One’s lead investigational therapy, tovorafenib (DAY101).
Sep 20, 2022 | businesswire.comFoundation Medicine, Inc. partners with Dayonebio
“Foundation Medicine, Inc. is proud to partner with Day One to provide access to tovorafenib through companion diagnostic development once approved and look forward to its ongoing collaboration to address significant unmet needs in pediatric oncology.”
Sep 20, 2022 | foundationmedicine.comFoundation Medicine, Inc. launched FoundationReport+, a new interactive digital report on Nov 14th 22'.
Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, today announced the launch of FoundationReport+, a new interactive digital report to enhance the useability of comprehensive genomic profiling (CGP) results.
Nov 14, 2022 | businesswire.com